Arena Pharma (ARNA) Agrees to Receive $100M from Deerfield Management
Up)
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it has entered into an agreement with Deerfield Management, a leading healthcare investment organization and significant Arena stockholder, to provide Arena with $100 million in funding through a credit facility.
Under the terms of the credit facility, Deerfield will provide Arena with $100 million within fifteen business days of signing. The closing is subject to customary closing conditions. Arena has agreed to pay Deerfield a transaction fee of 2.25% at the time of funding. The outstanding principal accrues interest until maturity in June 2013 at a rate of 7.75% per annum, payable quarterly, unless repaid earlier. The principal is required to be repaid as follows: 10% at the end of the first year, 20% at the end of the second year, 30% at the end of the third year and the remainder at the end of the fourth year. At any time Arena may, at its option, redeem any or all of the notes at par and apply such redemption amount against this repayment schedule.
At the closing of the $100 million funding, Arena will issue Deerfield warrants for 28 million shares of its common stock with an exercise price of $5.42 per share.
During the next two years, Deerfield may elect to provide Arena with up to an additional $20 million under the same terms, with the additional funding also maturing in June 2013. For each additional $1 million in funding, Arena will issue Deerfield additional warrants for 280,000 shares of its common stock with an exercise price of $5.42 per share. All of the warrants issued pursuant to the credit facility expire on the facility's maturity date.
Under the terms of the credit facility, Deerfield will provide Arena with $100 million within fifteen business days of signing. The closing is subject to customary closing conditions. Arena has agreed to pay Deerfield a transaction fee of 2.25% at the time of funding. The outstanding principal accrues interest until maturity in June 2013 at a rate of 7.75% per annum, payable quarterly, unless repaid earlier. The principal is required to be repaid as follows: 10% at the end of the first year, 20% at the end of the second year, 30% at the end of the third year and the remainder at the end of the fourth year. At any time Arena may, at its option, redeem any or all of the notes at par and apply such redemption amount against this repayment schedule.
At the closing of the $100 million funding, Arena will issue Deerfield warrants for 28 million shares of its common stock with an exercise price of $5.42 per share.
During the next two years, Deerfield may elect to provide Arena with up to an additional $20 million under the same terms, with the additional funding also maturing in June 2013. For each additional $1 million in funding, Arena will issue Deerfield additional warrants for 280,000 shares of its common stock with an exercise price of $5.42 per share. All of the warrants issued pursuant to the credit facility expire on the facility's maturity date.
You May Also Be Interested In
- Perception, Opportunity in Volatility - Research & Analysis on Arena Pharmaceuticals, Inc. and DryShips Inc.
- JAKKS Pacific (JAKK) Announces 4M Common Tender at $20/Share
- New York Mortgage Trust (NYMT) Prices 2.75M Offering at $6.65/Share
Create E-mail Alert Related Categories
Corporate NewsRelated Entities
Deerfield ManagementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
